Developing Biosimilars And Biobetters

Biosimilars are surmounting pharmaceutical business division from most recent three decades and deals appear to extend coherently. Advances in the biotechnology prompt to change and exposure of new natural items (biosimilars) to treat diverse life-debilitating illnesses. Biosimilars are organic medications that are conveyed after expiry of the patent of affirmed pioneer and include Hatch-Waxman act is the amendment to Federal, Food, Drug and Cosmetics act which established the modern system of approval of generics through Abbreviated New Drug Applications (ANDAs).

  • Key Aspects in Technical Development
  • Analysis of the Biosimilar Development Pipeline
  • Legal Issues and Implementation of the BPCI Act

Related Conference of Developing Biosimilars And Biobetters

November 09-11, 2017

4th European Biopharma Congress

Vienna, Austria
August 20-22, 2018

9th Asian Biologics and Biosimilars Congress

Tokyo, Japan

Developing Biosimilars And Biobetters Conference Speakers

Recommended Sessions

Related Journals

Are you interested in